[{"NetIncomeLoss_1_Q1_USD":-7855065.0,"CommonStockSharesIssued_0_Q1_shares":66962957.0,"LeaseAndRentalExpense_1_Q1_USD":68387.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q1_shares":11801266.0,"ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1_Q1_USD":1269316.0,"StockIssuedDuringPeriodValueNewIssues_1_Q1_USD":17461402.0,"AccruedLiabilitiesCurrent_0_Q1_USD":3816521.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q1_shares":64295143.0,"GeneralAndAdministrativeExpense_1_Q1_USD":1470656.0,"Cash_0_Q1_USD":47357599.0,"AdditionalPaidInCapitalCommonStock_0_Q1_USD":213766108.0,"Assets_0_Q1_USD":54334246.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":47357599.0,"IncreaseDecreaseInAccountsPayable_1_Q1_USD":227894.0,"StockIssuedDuringPeriodValueOther_1_Q1_USD":8518557.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":25979959.0,"ForeignCurrencyTransactionGainLossBeforeTax_1_Q1_USD":332634.0,"CashAndCashEquivalentsPeriodIncreaseDecrease_1_Q1_USD":18108581.0,"CommonStockValue_0_Q1_USD":66964.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1_Q1_pure":0.9616,"IncreaseDecreaseInAccruedLiabilities_1_Q1_USD":499947.0,"PrepaidExpenseCurrent_0_Q1_USD":398840.0,"PaymentsOfFinancingCosts_1_Q1_USD":263460.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1_Q1_pure":0.0062,"ShareBasedCompensation_1_Q1_USD":939314.0,"PreferredStockParOrStatedValuePerShare_0_Q1_USD":0.001,"ProceedsFromIssuanceOfCommonStock_1_Q1_USD":26243419.0,"NonoperatingIncomeExpense_1_Q1_USD":1600391.0,"AccountsPayableCurrent_0_Q1_USD":4216948.0,"LiabilitiesCurrent_0_Q1_USD":8033469.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-7871378.0,"InterestIncomeExpenseNet_1_Q1_USD":-1559.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q1_USD":-7795784.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0_Q1_shares":500000.0,"CommonStockSharesOutstanding_0_Q1_shares":66962957.0,"CurrentIncomeTaxExpenseBenefit_1_Q1_USD":59281.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-167532295.0,"StockholdersEquity_0_Q1_USD":46300777.0,"EarningsPerShareBasicAndDiluted_1_Q1_USD":-0.12,"OperatingExpenses_1_Q1_USD":9396175.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0_Q1_USD":8185000.0,"AllocatedShareBasedCompensationExpense_1_Q1_USD":939314.0,"PreferredStockSharesAuthorized_0_Q1_shares":10000000.0,"LiabilitiesAndStockholdersEquity_0_Q1_USD":54334246.0,"PreferredStockValue_0_Q1_USD":0.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1_Q1_pure":0.0,"IncreaseDecreaseInIncomeTaxesReceivable_1_Q1_USD":1728467.0,"IncomeTaxesReceivable_0_Q1_USD":6577807.0,"CommonStockSharesAuthorized_0_Q1_shares":100000000.0,"CommonStockParOrStatedValuePerShare_0_Q1_USD":0.001,"IncreaseDecreaseInPrepaidExpense_1_Q1_USD":-44999.0,"ResearchAndDevelopmentExpense_1_Q1_USD":7925519.0,"Ticker":"AVXL","CIK":"1314052","name":"ANAVEX LIFE SCIENCES CORP.","OfficialName":"Anavex Life Sciences Corp. Common Stock","form":"10-Q","period":"20201231","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"825317693.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Commercial Physical & Biological Resarch","Market":"NASDAQ","SP500":"nan","filed":"20210216"}]